Bristol-Myers Squibb Co. (BMY)

Bristol Myers is way over-sold at $20. It has not traded below $20 since 1996 and has met resistance at the $20 level on numerous occasions since then. Basic fundamentals are sound. Price/Sales could be a bit lower, but I think the "price" is not the problem, but rather "sales," which seem to have been laging for the past few periods. 1st Qtr '08 financial relults show a 20% increase in sales verses 1st qtr '07. Management reaffirmed 2008 guidance of $1.36 to $1.46 EPS and expects to "grow at a minimum of 15 percent compounded annual growth rate, from the 2007 base through 2010." A strong pipeline should help keep sales up in the coming years. The current dividend yield of 6% is a nice bonus. Should trade between $28.00 and $30.00 in two years.

This company has one of the best pipelines in the business. The Plavix dispute has cast a temporary cloud over what might be one of the best future cash flow drivers in the market. The loss of the Plavix patent will take a bite out of profits for the next couple of years, but the advent of drugs such as CTLA4 Ig should more than make up for it. Also, it's oncologic research is excellent. While we wait for developments to occur, we sit on top of a 5.4 % yeild, which is currently far higher than the treasury bond. Overall, an excellent investment that should outperform the market and its sector over the next 5-10 years.

The insiders are buying. The dividend is fat. They haven't eaten up another company like their bio/pharma bretheren (think PFE, MRK, Roche), so they don't have any rocky integrations to worry about. They have a stocked pipeline ( http://www.bms.com/research/pipeline/Pages/default.aspx).
Plus, we have a 1995 sale price. If you ever wanted to go back in time, well...

Blockbuster Plavix breathes a sigh of relief! Bristol-Myers Squibb is engaged in the discovery, development, licensing, and marketing of pharmaceutical and other health care products in the United States and other countries across the world.

Plavix is a medication for cardiovascular diseases, which is the leading cause of death in the U.S. as nearly 2,500 Americans die of cardiovascular diseases each day. Plavix was experiencing declining revenues in the recent quarters due to the launch of the generic version of Plavix by Apotex, which affected the company’s performance in the third quarter. However, the court’s recent ruling to block the generic version of Plavix has come as a huge reprieve for the company.

Bristol-Myers Squibb has a pipeline concentrated on drugs for oncology, which is expected to grow at a CAGR (compounded annual growth rate) of over 12%, thereby, driving the market to U.S. $30 billion by 2010.

With cancer being the second largest cause of death with more than 550,000 deaths and 1.4 million new cases diagnosed in the U.S. each year, the company launched SPRYCEL in July 2006. The response toward SPRYCEL has been encouraging. Moreover, considering the strong growth in drugs like AVAPRO, ABILIFY, REYATAZ, and ERBITUX, along with longer patent protection, it is believed that these drugs are all set to replace Pravachol’s revenue, which has gone generic in 2006.

The slowdown in revenues may continue in 2006. This is primarily due to the generic version of Plavix that is already in the market and cannot be called back according to the court’s ruling. However, it is believed that the strong growth of Plavix along with other major potential blockbuster drugs, and an impressive pipeline and ageing population will be the driving factors for the company in 2007.

At 21.46 BMY is trading close to its 52 week low with a 5.78% DY.

Last Morningstar fair value estimates were $26 and 23. S&P has a $26 target price.

BMY Was recommended by Chuck Carlson with Quadrix 1st of the year and gone down since like many others. i'll be getting paid to wait for it to come back and if it goes up $1 that's another 5%.

Fundamentally, has lowest P/S and highest 5 year EPS growth over

next 5 years among its peers.

change in CEO &/or ownership

only potential M&A make this stock attractive

Since falling from 52 bucks in Mar '02 to 21 bucks in Jul '02, Bristol-Myers has been pretty much locked into a trading range between 20 and 25 dollars. It made a mini-move in the past few days and may just be ready to move out of that range.

LOVE THE HEALTH CARE SECTOR-THIS LOOKS LIKE ANOTHER FEB. BUY & HOLD FOR ME!!!!!!!!!!

Bristol Myers has had many issues over the last five years. Problems with debt load, production facilites, patent expiration, lack of new drug pipeline etc. At these prices BMY is a good choice for a large pharma. Especially when compared to large rivals such as MRK and PFE. More upsidereward/less risk = larger returns

Great Dividend 4%, Restructure in progress and possible buyout.. A must own now

big farma a bit undervalued, look for it to outpace the S&P this year

BMY has significant troubles with pipeline and still may have a ways to go to get out of the woods from the poor management choices over the past few years. That being said the do a few things that I love:

1. Generate a lot of free cash flow
2. Have the demographics of the United States going the right direction
3. Pay a hefty dividend

While this stock will not be a home run anytime soon, it will steadily be the little train that can provide long term growth

Long term play in medical area. They are well managed, well deceplined, and will plow forward over the next several years.

-trading near 10 year low
-yield of 5%
-may be bought out anytime

it will be bought out

With its recent announcement of its plans to purchase the biotech company, Kosan Biosciences, BMS is strongly committing to increased research & development of new cancer drugs & treatments. All 3 of the major television networks recently announced a joint effort to increase awareness of & funding for cancer research in the form of  a prime-time, commercial-free 1 hour special. This effort is a reflection of the aging baby-boomer population's refusal to quietly accept their approx. 1 in 5 chance of getting & possibly dying from cancer. With this increased awareness comes increased funding which in turn spells increased profits for those companies that develop new drugs & treatments & with this acquisition, Bristol-Myers Squibb is positioning themselves to be a major player.

A large pharmaceutical company that will thrive as the aging baby boomers' health begins to decline, and their demand for medicine increases DRAMATICALLY!

Excellent dividend, good pipeline.